Characteristics of patients included in the nested case-control study.

<p>Characteristics of patients included in the nested case-control study.</p

Flow-chart of the study population of patients with hepatocellular carcinoma.

<p>Flow-chart of the study population of patients with hepatocellular carcinoma.</p

Kaplan Meier curve for cumulative incidence of thrombosis after liver transplantation.

<p>Kaplan Meier curve for cumulative incidence of thrombosis after liver transplantation.</p

Incidence rates of mortality and need of re-transplantation in patients with or without thrombosis.

<p>Incidence rates of mortality and need of re-transplantation in patients with or without thrombosis.</p

Characteristics of patients who underwent liver transplantation.

<p>Characteristics of patients who underwent liver transplantation.</p

Additional file 1: of Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis

Table S1. Characteristics of unmatched and matched treatment groups; The table shows the characteristics of patients who underwent TARE or sorafenib in unmatched and matched cohorts. (DOCX 14 kb

Additional file 3: of Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis

Appendix. CHEERS Checklist; The ISPOR CHEERS (Consolidated Health Economic Evaluation Reporting Standards) checklist shows recommended items to be included in reports of economic evaluations of health interventions. (PDF 108 kb

Additional file 4: of Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis

Table S2. Mean annual costs per patient for intermediate and advanced stages HCC related to TARE and sorafenib treatments; The table reports, for TARE and sorafenib, mean annual costs per patient for the following cost categories: first-line treatment, management of adverse events, visits/exams, subsequent treatments. (DOCX 18 kb